<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609540</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongCHI-14</org_study_id>
    <nct_id>NCT04609540</nct_id>
  </id_info>
  <brief_title>Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC</brief_title>
  <official_title>Pyrotinib Combined With Trastuzumab and Chemotherapy in HER2-positive Metastatic Breast Cancer Patients- a Multicenter Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in&#xD;
      China, and to explore the relationship between progression free survival and treatment&#xD;
      pattern.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>The time from starting pyrotinib until disease progression or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>1 year</time_frame>
    <description>The time from starting pyrotinib until death, regardless of cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients with complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with adverse events which were collected at 6 and 18 months after the start of pyrotinib</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pyrotinib and Trastuzumab group</arm_group_label>
    <description>Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Dual anti-HER2 therapy</description>
    <arm_group_label>Pyrotinib and Trastuzumab group</arm_group_label>
    <other_name>Pyrotinib</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HER2 positive Metastatic Breast Cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  woman, age &gt; 18 years old&#xD;
&#xD;
          -  Diagnosed with HER2 +Metastatic Breast Cancer&#xD;
&#xD;
          -  Pyrotinib Combined With Trastuzumab And Chemotherapy for at least one cycle, starting&#xD;
             from 2020.11.01-2021.10.31&#xD;
&#xD;
          -  Available medical history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incomplete medical history&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhiyong Yu, PhD</last_name>
    <phone>86-13355312277</phone>
    <email>drzhiyongyu@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chao Li, MD</last_name>
    <phone>86-15665851082</phone>
    <email>lichao19890305@126.com</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Zhiyong Yu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

